BNET Industries
Cepheid (CPHD) is in the Health Care Industry
- Revenue
- Dec 31 2007
- $129.4M
- Profit
- Dec 31 2007
- ($21.4M)
- Market Cap
- Sep 04 2008
- $1.0B
Latest News and Analysis
Best and Worst Performing Stocks on Earnings
Hickey and Walters Bespoke submit: The average US stock went up 0.34% on the first trading day following their earnings reports during the second quarter reporting period. That's a pretty good number considering the negative sentiment we saw leading up to earnings season. Now that Wal-Mart WMT has...
Be Selective with Medical Device Companies
Zacks.com submits: With earnings season beginning to wind down in the medical devices and supplies industry, we figured it would be a good time to check in with Zacks senior analyst Tom Park. We were looking to see if there are any attractive buys among his coverage....
Cepheid Second Quarter 2008 Earnings Call Transcript
Cepheid CPHD Q2 2008 Earnings Call
Cepheid Q1 2008 Earnings Call Transcript
Cepheid Q1 2008 Earnings Call Transcript
Additional Resources
BellwetherReport.com Analyst Opinions on INTU, SKIL, CPHD and LMDIA
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
Cepheid to Webcast Upcoming Financial Presentations
SUNNYVALE, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Cepheid today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast. Thomas Weisel Partners Healthcare Conference, Boston, MA ...
Zacks Analyst Interview Highlights: Cepheid, BioSphere Medical and Immucor
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Tom Park, who discusses Cepheid (Nasdaq: CPHD), BioSphere Medical (Nasdaq: BSMD) and Immucor (Nasdaq: BLUD). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2678. ...
BeaconEquity.com Issues Technical Trade Alerts on Market Movers: YHOO, GOOG, DENN, RFMD, TRID, CPHD
DALLAS, July 30 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://beaconequity.com/m Today's Trade Alerts include: Yahoo! Inc. , Google Inc. , Denny's Corp. (Nasdsaq: DENN),...
Cepheid Introduces GeneXpert® Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
GeneXpert Infinity-48 is the World's First Fully-Automated Random Access Molecular Diagnostic Testing System; On Display at AACC Meeting SUNNYVALE, Calif., July 29 /PRNewswire-FirstCall/ -- Cepheid today introduced its GeneXpertR Infinity-48 high-throughput system at the 2008 American Association for Clinical Chemistry Annual Meeting in Washington, D.C. The...
Cepheid GeneXpert® System and Xpert™ MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of 'Start Clean' Strategy
State of Victoria, Australia 'Start Clean' Strategy Requires Public Reporting of HAIs in all 76 Public Hospitals by End of 2009 SUNNYVALE, Calif., July 28 /PRNewswire-FirstCall/ -- Cepheid today announced that the State of Victoria has selected Cepheid's GeneXpertR System and XpertTM MRSA test for screening...
BellwetherReport.com Analyst Report on EPCT, AFFX, CPHD and CROX
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
Cepheid Reports Second Quarter Revenue of $42.1 Million
65 Percent Increase in Product Sales Driven by Robust MRSA Growth SUNNYVALE, Calif., July 24 /PRNewswire-FirstCall/ -- Cepheid today reported revenue for the second quarter of 2008 of $42.1 million, an increase of 55% over the second quarter of fiscal 2007. Net loss was $7.5...
IBC Announces D2D: IBC's Discovery2Diagnostics Conference & Exhibition
IBC's Discovery2Diagnostics Conference &Exhibition will be held October 20-22, 2008 at the Manchester Grand Hyatt,in San Diego, CA. Developed through content from the 15th Annual Chips toHits®, 7th Annual Biomarkers, and 7th annual Molecular Diagnostics, D2Dbrings together discovery technology, biomarkers, molecular diagnostics andmolecular theranostics. The conference agenda...
Mergent, Inc. Announces Quarterly Rebalancing of HealthShares™ Indexes
NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the quarterly rebalancing of the Indexes. The following securities will be added and deleted in the Indexes effective before...
Cepheid Management to Present at the 7th Annual Needham Medical Technology and Biotechnology Conference and William Blair's 28th Annual Growth Stock Conference
* Updated Investor Presentation Available on Cepheid Web Site SUNNYVALE, Calif., June 4 /PRNewswire-FirstCall/ -- Cepheid announced today that the Company will webcast presentations at the following investor conferences: -- The 7th Annual Needham Medical Technology and Biotechnology ...
Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
MRSA, GBS and EV Expand GeneXpertR Test Menu in Canada and Mexico SUNNYVALE, Calif., June 3 /PRNewswire-FirstCall/ -- Cepheid today announced that Health Canada issued a medical device license for XpertTM GBS, for the rapid detection of Group B Streptococcus GBS, and XpertTM EV enterovirus, for...
Hospitals, Healthcare Providers to Save with Premier Agreements for Molecular Rapid Qualitative Screening
CHARLOTTE, N.C. -- Premier Purchasing Partners, LP, has awarded new agreements for molecular rapid qualitative screening products, reagents and services to BD Diagnostics GeneOhm of San Diego and Cepheid Inc. of Sunnyvale, Calif. This 36-month debut portfolio, which includes new technology, was effective May 1, 2008; it is...
Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
SUNNYVALE, Calif., May 12 /PRNewswire-FirstCall/ -- Cepheid today announced it has signed a group purchasing contract with Premier, Inc., one of the largest U.S. Group Purchasing Organizations GPOs with more than 1,500 participating hospitals and 42,000 other healthcare sites. In conjunction with this agreement, Cepheid has also signed...
Breaking News Alert: UDTT!
Wall Street Press Wire( www.WallStreetPressWire.com ) is please to highlight its "stocks on themove" for Tuesday. Our list includes: Universal Detection Technology(OTCBB: UDTT), Cepheid (NASDAQ: CPHD) and Raytheon Company (NYSE: RTN). Wall Street Press Wire is continuing its in-depth coverage of UniversalDetection Technology (OTCBB: UDTT), a developer of early-warning monitoringtechnologies...
Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
SUNNYVALE, Calif., May 6 /PRNewswire-FirstCall/ -- Cepheid announced today that the Company will present at the following investor conferences: -- The Robert W. Baird Growth Stock Conference on May 13 at 12:15 p.m. EDT at The Four Seasons Hotel in Chicago ...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
- Incorporated: 1996
- CEO: Mr. John L. Bishop
- Employees: 307
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for genetic testing in the Clinical Molecular Diagnostics, Industrial and Biothreat markets. Co.'s systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Co.'s SmartCycler® system integrates DNA amplification and detection to allow rapid analysis of a sample. Co.'s GeneXpert® system integrates sample preparation in addition to DNA amplification and detection. Co. conducts sales of products within its market through both direct sales and distribution channels worldwide.
Key Competitors
Cepheid Company Info
Board of Directors
Mr. Thomas L. Gutshall
Chairman
Mr. John L. Bishop
Dr. David H. Persing Ph.D.
Mr. Thomas D. Brown
Mr. Robert J. Easton
Ms. Cristina H. Kepner
Mr. Dean O. Morton
Mr. Mitchell D. Mroz
Mr. Hollings C. Renton
Contact Information
904 Caribbean Drive
Sunnyvale, CA
408 541 4191